Prostate cancer: EDAP lands FDA date for therapeutic ultrasound

EDAP TMS lands a July date with FDA advisors to review therapeutic ultrasound in treatment of localized prostate cancer.

France-based EDAP TMS SA will get its day with the FDA next month, when the agency's expert advisors will review EDAP's Ablatherm-HIFU therapeutic ultrasound technology for treatment of prostate cancer.

EDAP TMS SA, Food & Drug Administration (FDA)

News Well, Regulatory/Clearance, Food & Drug Administration (FDA), Pre-Market Approval (PMA), Prostate, Ultrasound

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/SnXRPb